---
title: "Eli Lilly: Oral GLP-1RA orforglipron outperforms oral semaglutide in head-to-head studies"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/257803131.md"
description: "On September 17th, Eli Lilly announced positive results from the ACHIEVE-3 study, which evaluated the safety and efficacy of the oral GLP-1RA drug orforglipron compared to oral semaglutide in patients with type 2 diabetes. The study showed that orforglipron outperformed semaglutide in both blood sugar control and weight loss over 52 weeks, with all dosage groups achieving the primary and key secondary endpoints"
datetime: "2025-09-17T23:36:26.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/257803131.md)
  - [en](https://longbridge.com/en/news/257803131.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/257803131.md)
---

# Eli Lilly: Oral GLP-1RA orforglipron outperforms oral semaglutide in head-to-head studies

On September 17th local time, Eli Lilly announced positive top-line results from the ACHIEVE-3 study, which is an open-label, randomized phase 3 clinical trial assessing the safety and efficacy of orforglipron compared to oral semaglutide in 1,698 adult participants with type 2 diabetes who had inadequate blood sugar control on metformin treatment. The study lasted 52 weeks and compared the results of orforglipron with oral semaglutide in terms of blood sugar control and weight loss across four active treatment groups. At 52 weeks, all dose groups of orforglipron achieved the primary endpoint and all key secondary endpoints, showing superior improvements in hemoglobin A1c and weight compared to oral semaglutide

### Related Stocks

- [LLY.US](https://longbridge.com/en/quote/LLY.US.md)

## Related News & Research

- [Meet the Nvidias of power - 5 stocks winning Big Tech's $700 billion AI energy grab](https://longbridge.com/en/news/286680757.md)
- [Missed Nvidia? Why Tech Analyst Beth Kindig Calls Bloom Energy Tech's 'Biggest Outperformer' After 217% Rally In 2026](https://longbridge.com/en/news/286756465.md)
- [Nvidia Will Report Q1 Earnings on May 20 — Options Traders Expect an 8.65% Move in NVDA Stock](https://longbridge.com/en/news/286763191.md)
- [Marvell (MRVL) More than Doubled This Year. The AI Opportunity Still Looks Bigger](https://longbridge.com/en/news/286762422.md)
- [Lululemon urges vote for board declassification as founder Chip Wilson seeks three seats](https://longbridge.com/en/news/286759861.md)